Predictive performance and clinical application of COV50, a urinary proteomic biomarker in early COVID-19 infection: a prospective multicentre cohort study.
Staessen JA, Wendt R, Yu YL, Kalbitz S, Thijs L, Siwy J, Raad J, Metzger J, Neuhaus B, Papkalla A, von der Leyen H, Mebazaa A, Dudoignon E, Spasovski G, Milenkova M, Canevska-Taneska A, Salgueira Lazo M, Psichogiou M, Rajzer MW, Fuławka Ł, Dzitkowska-Zabielska M, Weiss G, Feldt T, Stegemann M, Normark J, Zoufaly A, Schmiedel S, Seilmaier M, Rumpf B, Banasik M, Krajewska M, Catanese L, Rupprecht HD, Czerwieńska B, Peters B, Nilsson Å, Rothfuss K, Lübbert C, Mischak H, Beige J; CRIT-CoV-U investigators.
Staessen JA, et al. Among authors: lubbert c.
Lancet Digit Health. 2022 Oct;4(10):e727-e737. doi: 10.1016/S2589-7500(22)00150-9. Epub 2022 Aug 31.
Lancet Digit Health. 2022.
PMID: 36057526
Free PMC article.
The cost reductions associated with 1 day less hospitalisation per 1000 participants were million Euro (M) 0.887 (5-95% percentile interval 0.730-1.039) in participants at a low risk (COV50 <0.04) and M2.098 (1.839-2.365) in participants at a high risk (COV50 0.04). ...
The cost reductions associated with 1 day less hospitalisation per 1000 participants were million Euro (M) 0.887 (5-95% percentile in …